PubMed Health⌕ Search

PubMed · 12935728

Postmortem bacteriology in forensic pathology: diagnostic value and interpretation.

Abstract

The proof of a pathogenetic germ can be of evidential value for the medico-legal expertise concerning etiopathogenetic conclusions towards a causal relationship between infection and fatal outcome. In specific cases the forensic pathologist may be confronted with the decision whether cultures for postmortem bacteriological investigations should be obtained at autopsy. The present review surveys the value and practicability of postmortem bacteriological cultures in the light of the literature. The most promising media for postmortem bacteriological cultures are spleen and heart blood. In contrast, postmortem lung culture results are often unreliable due to frequently false positive results. The collection of specimens from at least two different sampling sites should be the standard procedure in cases where an underlying (potentially fatal) infection is presumed. Multiple postmortem cultures from different sampling sites raise the probability to identify the etiologic agent of antemortem infection. A careful correlation of culture results from different anatomical sampling sites with autopsy and histological findings is essential for the differentiation between vitally acquired infection and postmortem contamination. Various factors (e.g. the time interval between death and sampling of specimens, agonal spread of microorganisms or preceding antibiotic therapy prior to death) may limit the diagnostic utility of postmortem culture results. Contamination of specimens may, e.g. originate from inadequate sampling techniques, use of unsuitable transport media or postmortem growth of bacteria. The number of contaminated postmortem cultures increases when bowel manipulation or evisceration occurs prior to sampling and is depending on the anatomy of the sampling site. Polymicrobial growth can be considered contamination in the majority of cases. For the medico-legal expertise a thorough histological examination of inner organs and tissues is needed; the histological section has to represent the sampling site for culture. The presence of an underlying infection can be proven when postmortem bacteriological cultures yield a primary infectious pathogen and a cellular response in the affected tissue can be detected on the histopathological level. Postmortem bacteriology can be regarded as a reliable diagnostic tool for postmortem quality control of preceding diagnostic and therapeutic procedures and can serve as an additional indicator of nosocomial infections within a specific hospital environment. From the medico-legal point of view, a more widespread application of this valuable investigative procedure, that adds to diminish the number of otherwise unresolved deaths in forensic autopsy practice, is desirable.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Tsokos, K Püschel. 2001. Postmortem bacteriology in forensic pathology: diagnostic value and interpretation.. https://doi.org/10.1016/s1344-6223(01)00002-5

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗